RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Primary products include the VanishPoint insulin syringe and the Patient Safe syringe. Manufacturing occurs in Little Elm, Texas, and via a contract manufacturer in China (Double Dove).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 61% to $8.5 million, driven by a 47.9% increase in domestic unit sales and higher average prices. International sales volume decreased 14.3%.
• Profitability Improvement: Gross profit increased 181% due to higher revenues and a 3.9% decrease in the average cost of manufactured product per unit. Operating loss narrowed by 46%.
• Cash Flow Turnaround: Operating cash flow swung from a use of $3.0 million in Q1 2009 to a provision of $1.4 million in Q1 2010, primarily due to a significant decrease in accounts receivable ($4.8 million).
• Inventory Build-up: Inventories increased by $1.6 million (23%) due to a build-up of finished goods related to the Department of Health and Human Services (DHHS) Swine Flu program.
• Impairment Charge: The Company recognized a non-cash impairment charge of $163,039 on R&D equipment intended for outsourcing.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• DHHS Program Impact: The Swine Flu vaccination program, which accounted for 24.4% of 2009 revenues, ended in December 2009. Q1 2010 included $7.1% of sales attributable to orders placed in 2009. No similar program is confirmed for the remainder of 2010.
• Cost Cutting: Management implemented workforce reductions (16% in Q2 2009) and salary cuts to conserve cash. These measures reduced operating expenses by approximately $270,000 in compensation and $176,000 in other costs.
• Adjusted Earnings: Management notes that excluding litigation costs and stock option expense (non-cash), the Company would have reported net income of approximately $700,000 for the quarter.
• Liquidity: The Company maintains strong liquidity with cash comprising 37.5% of total assets. A $2.5 million loan matured in late March 2010 and was paid off in April 2010; the Company may seek replacement financing.

Risks and Contingencies

• Legal Proceedings:
  • Abbott Laboratories: Ongoing lawsuit alleging fraud and breach of contract; trial set for July 2010. Abbott has counterclaimed for over $6 million.
  • Becton Dickinson (BD): Jury verdict in November 2009 awarded the Company $5 million for patent infringement, but no final judgment has been entered. BD has counterclaimed for invalidity.
• Supplier Concentration: Approximately 65.3% of finished products in Q1 2010 were sourced from Double Dove in China. Disruption could impact supply of key products.
• Preferred Stock Dividends: Significant dividends are in arrears across multiple series of Class B Preferred Stock (totaling over $15 million in cumulative arrearages). A dividend of $876,555 was declared for Series I and II, payable July 15, 2010.

Investor Verification Checklist

• Debt Refinancing: Verify if the Company secures replacement financing for the $2.5 million loan paid off in April 2010.
• Legal Resolution: Monitor the status of the $5 million BD verdict and the upcoming July 2010 trial against Abbott Laboratories.
• Revenue Sustainability: Assess the ability to maintain revenue levels post-DHHS Swine Flu program without a similar government contract.
• Supplier Risk: Evaluate the stability of the supply chain with Double Dove (China) and the capacity of domestic facilities to absorb production if needed.
• Preferred Stock Obligations: Review the impact of cumulative preferred dividend arrearages on future cash flow and common shareholder equity.